Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: SUPN SUPERNUS PHARMACEUTICALS, INC. 8-K

Supernus to merge with Indivior in all-stock deal; shareholders to receive 1.5401 Indivior shares

Filed August 3, 2026 · Period ending August 1, 2026 · ~2 min read

Key Changes

  • high

    Supernus shareholders will receive 1.5401 Indivior shares per share in a fixed-ratio all-stock merger, owning 43.5% of the combined company; Indivior shareholders will own 56.5% and receive a $1 billion special dividend before closing.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    Indivior will pay a $1 billion special dividend to its shareholders immediately before closing, funded by a $650 million term loan from Citibank and existing cash; pro forma net debt will be $878 million with leverage below 1x.

    Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
  • high

    The combined company expects $2.2 billion in pro forma revenue, $888 million in adjusted EBITDA, and $125 million in annual cost synergies; closing is expected in Q4 2026 subject to shareholder and regulatory approvals.

    Exhibit 99.1 view on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TRS 10-Q) is open in full — no account needed.

Partner

Trade SUPN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify